Direct Lobbying Transparency
| Overall Assessment | Comment | Score |
|---|---|---|
| Moderate | AstraZeneca provides a moderate level of transparency around its climate-related lobbying. It identifies two specific pieces of legislation it has engaged on—the EU F-gas Regulation and the PFAS restriction proposal—showing some clarity about the policy arena in which it is active. The company describes several ways it seeks to influence these files, including “submitted responses to the ECHA public consultation on the PFAS restriction proposal,” issuing a public position to the EU consultation on the F-gas Regulation, and advocating through trade associations and the Sustainable Markets Initiative Health Systems Task Force, and it names the principal targets of these efforts (ECHA, EU and UK regulators). AstraZeneca also discloses the outcomes it is pursuing, stating that it is “advocating for the EU to maintain proposed reference values for medical F-gas in 2024-2026 through to 2030” and is “calling on the EU to establish a phasedown schedule which protects patient safety and supports the transition to low-GWP alternatives.” However, beyond these two policy areas the company does not list additional climate policies, the details of its direct engagement methods are limited, and no further specific legislative changes or timelines are set out, leaving some gaps in overall transparency. | 2 |